Screener
Bicara Therapeutics BCAX Operating Income
Operating Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033429
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | 45,518 | 27,758 |
| General and administrative | 12,742 | 7,455 |
| Total operating expenses | 60,242 | 41,788 |
| Loss from operations | (60,242) | (41,788) |
| Other income | ||
| Interest income | 4,083 | 5,014 |
| Total other income | 4,083 | 5,014 |
| Net loss before income taxes | (56,159) | (36,774) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bicara Therapeutics's operating income?
- Bicara Therapeutics (BCAX) reported operating income of -$60.24M in Q1 2026.
- How has Bicara Therapeutics's operating income changed year-over-year?
- Bicara Therapeutics's operating income decreased by 44.2% year-over-year, from -$41.79M to -$60.24M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Bicara Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude